Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021
Related Posts
Reported Late Monday Feb. 27, Eisai Co. And Biogen Inc. Announce Biologics License Application For Lecanemab Designated For Priority Review By China National Medical Products Administration
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", , Biogen", , ))))
Wells Fargo Maintains Equal-Weight on Ingevity, Raises Price Target to $74
Wells Fargo analyst Michael Sison maintains Ingevity (NYSE:NGVT) with a Equal-Weight and raises the price target from $70 to $74.
Mereo’s Alvelestat Shows Encouraging Biomarker Data In Bronchiolitis Obliterans Syndrome
Mereo BioPharma Group plc (NASDAQ:MREO) has announced data from an interim analysis of an investigator-initiated study of alvelestat, in patients with…